Clinical trial design for children with rare conditions remains difficult due to small cohorts and complex endpoints, despite supportive regulations https://www.einpresswire.com/article/834691992/orphan-drugs-market-to-reach-usd-486-51-billion-by-2032-on-rare-disease-focus-datam-intelligence